NeOnc Technologies Holdings, Inc. Common Stock (NTHI) is a Healthcare · Biotechnology company listed on NASDAQ. Price $3.31 (-2.93%), Market cap $0.14B, 52-week low–high $3.35 ~ $12.09.
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. The company was incorpo
Financial statements, price targets, institutional (13F) holdings and related news for NeOnc Technologies Holdings, Inc. Common Stock are updated in real time on BlackAll Trade.
NeOnc Technologies Holdings, Inc. Common Stock trades at $3.31 (-2.93%). Real-time quotes and charts are available on BlackAll Trade.
NeOnc Technologies Holdings, Inc. Common Stock has a market cap of about $0.14B.
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified fo